The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Optimizing treatment for patients with SCD beyond curative options
Susan Creary, MD, Nationwide Children’s Hospital, Columbus, OH, comments on a session at ASH 2024, which focused on optimizing treatment for patients with sickle cell disease (SCD) beyond just pursuing curative options. Dr Creary highlights the need for practical guides to selecting disease-modifying medicines, considering factors such as adherence, availability, and patient expectations and preferences. She also emphasizes the need for more evidence-based and patient-guided management tools as the treatment landscape evolves. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We were fortunate that ASH really wanted to highlight ways that we could optimize treatment for people with sickle cell disease beyond just pursuing curative and transformative options. So, my part of our session was actually to discuss the disease-modifying medicines that have been approved for sickle cell disease, and then really go into how you select those and providing a practical guide to clinicians about how we can go about selecting them based on the available clinical evidence, patients’ and families’ preferences, and then just availability and access...
We were fortunate that ASH really wanted to highlight ways that we could optimize treatment for people with sickle cell disease beyond just pursuing curative and transformative options. So, my part of our session was actually to discuss the disease-modifying medicines that have been approved for sickle cell disease, and then really go into how you select those and providing a practical guide to clinicians about how we can go about selecting them based on the available clinical evidence, patients’ and families’ preferences, and then just availability and access. And then we also talked about ways that we could optimize them after we’d started those therapies. So we wanted to know what are the factors that might contribute to a patient having a suboptimal response. So things like not consistently taking it or non-adherence. We wanted to know about whether or not patients were optimally dosed on the medication that they were receiving and whether or not the treatment outcomes were as expected with what the patients initially had planned for their expectations with that treatment. And then finally, we went on to discuss that there are limited resources available to guide clinicians and to guide patients about how to use these medications, how to use them in combination. But as the treatment landscape for sickle cell disease changes, we need better, more patient-guided and evidence-based guided management tools to help us select the right therapy for the right patient.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
